Convalescent plasma for covid-19

Estcourt, Lise J; Roberts, David

doi:10.1136/bmj.m3516

Cited by 33 publications

(40 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since the onset of the outbreak, due to the lack of speci c treatment options, convalescent plasma of recovered patients with COVID-19 has been used to treat patients with moderate or severe COVID-19 illness 23,24 . The FDA, USA has issued an emergency use authorization for the use of convalescent plasma as it was believed that it may be effective 23 . Although randomized clinical trials have not been conducted to determine the e cacy of this treatment, as use of convalescent plasma depends on the presence of high levels of NAbs, it is recommended to test the presence of high titres, before selection of potential donors 25,26 . The relationship between the appearance of NAb with duration of virus shedding has not been previously studied.…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness

Jeewandara

Jayathilaka

Gomes

et al. 2020

Preprint

View full text Add to dashboard Cite

In order to support vaccine development, and to aid convalescent plasma therapy, it would be important to understand the kinetics, timing and persistence of SARS-CoV2 neutralizing antibodies (NAbs), and their association with clinical disease severity. Therefore, we used a surrogate viral neutralization test to evaluate their levels in patients with varying severity of illness, in those with prolonged shedding and those with mild/asymptomatic illness at various time points.Patients with severe or moderate COVID-19 illness had earlier appearance of NAbs at higher levels compared to those with mild or asymptomatic illness. Furthermore, those who had prolonged shedding of the virus, had NAbs appearing faster and at higher levels than those who cleared the virus earlier. During the first week of illness the NAb levels of those with mild illness was significantly less (p=0.01), compared to those with moderate and severe illness. At the end of 4 weeks (28 days), although 89% had Nabs, 38/76 (50%) in those with >90 days had a negative result for the presence of NAbs. The Ab levels significantly declined during convalescence (>90 days since onset of illness), compared to 4 to 8 weeks since onset of illness. Our data show that high levels of NAbs during early illness associated with clinical disease severity and that these antibodies declined in 50% of individuals after 3 months since onset of illness.

show abstract

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness

Jeewandara

Jayathilaka

Gomes

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Following suggestions of benefit from observational studies, convalescent plasma was given to more than 100 000 patients admitted to hospital with covid-19 in the US between April and August—under the FDA’s expanded access treatment protocol 10. The authors of the safety update on the first 20 000 recipients said their results provided “robust evidence that transfusion of CP [convalescent plasma] is safe.”11…”

mentioning

confidence: 99%

Convalescent plasma is ineffective for covid-19

Pathak

2020

BMJ

View full text Add to dashboard Cite

show abstract

“…195,196 Hyperimmune globulin is currently used for post-exposure prophylaxis in the treatment of several viral infections, including hepatitis B (HBV), rabies, tetanus toxin, varicella-zoster, rubella, measles, etc. 30,[197][198][199] The COVID-19 pandemic attracted much new research to develop therapeutic drug options, [200][201][202][203] including CPT 80,88,93,102,113,204 to treat patients as no specific medication is available. Initially, the US FDA approved and served EUA, 80,205 regarding CPT but later amended the earlier policy (September-2-2020).…”

Section: Discussionmentioning

confidence: 99%

<p>Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic</p>

Samad¹,

Sodunke²,

Banna³

et al. 2020

RMHP

View full text Add to dashboard Cite

The world is striving against the severe crisis of the COVID-19 pandemic. Healthcare professionals are struggling to treat their patients based on nonspecific therapies. Amidst this uncertainty, convalescent plasma therapy (CPT) has appeared to be an interim adjuvant therapy for severely ill patients of COVID-19 until long-term clinical trial treatment options are available. Considering the transfusion-related hazards, especially lung injuries and microbial transmission, where sensitivity is not ensured, rigorous trials should be conducted to determine this therapy's efficacy. Moreover, the ratio of recovered cases to plasma donors is not satisfying, which questioning this therapy's availability and accessibility. Although some countries are making the treatment free, the attributable cost mandates a justification for its suitability and sustainability. Our article aimed to review the published facts and findings of CPT's effectiveness in lowering the mortality rate of COVID-19. This pandemic showed that healthcare systems worldwide need core reform. A unified global collaboration must align and coordinate to face the current pandemic and enhance world readiness for future outbreaks based on health equity and equality.

show abstract

Convalescent plasma for covid-19

Abstract: Authorisation in the US was premature, and a missed opportunity

Cited by 33 publications

References 15 publications

SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness

SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness

Convalescent plasma is ineffective for covid-19

<p>Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic</p>

Contact Info

Product

Resources

About